Forte Biosciences, Inc. Announces 2023 EPS $(1.00) Vs $(0.80) YoY
Forte Biosciences, Inc. Announces 2023 EPS $(1.00) Vs $(0.80) YoY
2023 Operating Results
2023 年經營業績
Research and development expenses were $21.9 million for the year ended December 31, 2023, compared to $5.6 million during the same period in 2022. The increase of $16.3 million was primarily due to a net increase of approximately $9.9 million in manufacturing expense, a net increase of approximately $6.0 million in preclinical and clinical expenses as our FB-102 program entered the clinic, and a net increase in payroll and related expenses of approximately $0.4 million primarily due to an increase in headcount.
截至2023年12月31日的財年，研發費用爲2190萬美元，而2022年同期爲560萬美元。增加1,630萬美元的主要原因是製造費用淨增加約990萬美元，隨着我們的 FB-102 計劃進入臨床，臨床前和臨床費用淨增加約600萬美元，工資和相關費用淨增加約40萬美元，這主要是由於員工人數的增加。
General and administrative expenses were $10.6 million for the year ended December 31, 2023, compared to $8.3 million for the same period in 2022. The increase of $2.3 million was primarily due to an increase in professional and legal expenses of $2.6 million, an increase in other expenses of $0.4 million, including rent and personnel expenses, partially offset by a reduction in stock-based compensation expense of $0.7 million.
截至2023年12月31日的財年，一般和管理費用爲1,060萬美元，而2022年同期爲830萬美元。增加230萬美元的主要原因是專業和法律費用增加了260萬美元，包括租金和人事支出在內的其他支出增加了40萬美元，但股票薪酬支出減少了70萬美元，部分抵消了這一增加。
Net losses per share were ($1.00) and ($0.80) for the years ended December 31, 2023 and 2022, respectively.
截至2023年12月31日和2022年12月31日止年度的每股淨虧損分別爲（1.00美元）和（0.80美元）。
Forte ended 2023 with approximately $37.1 million in cash and cash equivalents. Forte had approximately 36.3 million shares of common stock outstanding as of December 31, 2023.
截至2023年，Forte擁有約3710萬美元的現金和現金等價物。截至2023年12月31日，Forte的已發行普通股約爲3630萬股。
譯文內容由第三人軟體翻譯。